Bronchopulmonary dysplasia (BPD), a chronic lung disease affecting very premature infants, is a major cause of mortality and long-term morbidities despite of current progress in neonatal intensive care medicine. Though there has not been any effective treatment or preventive strategy for BPD, recent stem cell research seems to support the assumption that stem cell therapy could be a promising and novel therapeutic modality for attenuating BPD severity. This review summarizes the recent advances in stem cell research for treating BPD. In particular, we focused on the preclinical data about stem cell transplantation to improve the lung injury using animal models of neonatal BPD. These translational research provided the data related with the safety issue, optimal type of stem cells, optimal timing, route, and dose of cell transplantation, and potency marker of cells as a therapeutic agent. Those are essential subjects for the approval and clinical translation. In addition, the successful phase I clinical trial results of stem cell therapies for BPD are also discussed.
INTRODUCTION
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that usually occurs in premature infants receiving prolonged oxygen supplementation and ventilator support. The risk of de veloping BPD correlates with the extent of immaturity (1) . Re cent improvements in the survival of very preterm infants throu gh advances in neonatal intensivecare medicine have, there fore, made the task of protecting the extremely immature lungs against BPD increasingly challenging. BPD remains an impor tant cause of mortality and longterm respiratory morbidities such as airway hyperreactivity, poor lung function, and low ex ercise capacity (26) . In addition, neurologic morbidities such as developmental delay and cerebral palsy (7) are also com mon. The histopathological characteristics of BPD include im paired alveolarization and interstitial fibrosis (8, 9) . Prolonged oxygen exposure of newborn rat pups results in decreased alve olarization and increased lung fibrosis, thereby simulating the histopathology of human BPD (9, 10) . Inflammatory responses are believed to play critical roles in the lung injury process lead ing to the development of BPD (1) . Currently, no effective treat ments beyond supportive therapies are available for BPD. There fore, development of new therapeutic modalities to improve the prognosis of BPD in preterm infants is an urgent priority.
Recently, current literature has shown that the exogenous administration of stem cells significantly attenuated neonatal hyperoxic lung injuries (1118). These findings suggest that stem cell transplantation might be a new and promising thera peutic modality for the treatment of BPD. In this review, we summarize the recent advances in stem cell research for treat ment of BPD. In particular, we focus on the preclinical data re garding the important issues for clinical translation such as the optimal cell type, route, dose, and timing of stem cell therapy. Furthermore, the successful phase I clinical trial results of stem cell therapies for BPD are discussed.
PRECLINICAL RESEARCH DATA
Determining the optimal cell type Among the various stem cells, the selection of a single appro priate stem cell that ultimately exhibits the best therapeutic ef ficacy in protecting against BPD is a difficult challenge. Embry onic stem cells are pluripotent cells capable of generating all cell types from three germ layers. However, the high tumorige http://dx.doi.org/10.3346/jkms.2015.30.5.509 nicity and ethical concerns of destroying embryos for their ac quisition have limited their availability for research and clinical applications (19) .
Mesenchymal stem cells (MSCs) are the most extensively ex amined cell type used in experimental models of BPD (1318, 20) . MSCs are broadly distributed in the body, and could be isolated from adult tissues such as the bone marrow, adipose tissue, and gestational tissues such as the placenta, Wharton's jelly, and umbilical cord blood (UCB). The umbilical cord and placenta are medical wastes that are usually discarded at birth, and therefore, MSCs obtained from gestational tissues seem to be particularly attractive (21). In addition to their easy attain ability, MSCs derived from gestational tissues showed less anti genicity (21), and higher proliferation capacity and paracrine potency compared with adult tissuederived MSCs (22). Even within the same adult tissue origin, donor age negatively im pacted the expansion and differentiation potential of the MSCs (23, 24) . Collectively, these findings suggest that MSCs derived from postpartum associated tissues such as UCB or Wharton's jelly might be the optimal cell source for future clinical applica tions, in protecting premature infants against BPD.
Therapeutic potential and protective mechanisms of MSCs for BPD
The therapeutic efficacy of MSCs has been tested in the hyper oxiainduced neonatal rodent or murine model of BPD, and was reported to improve survival, and suppress oxidative stress and inflammation (11, 1318, 20) . In addition, it attenuated the impaired alveolar growth, lung vascular injuries, fibrosis, and the associated pulmonary hypertension (11, 1318, 20) . These findings support the assumption that stem cell transplantation might be a promising novel therapeutic approach for BPD.
The beneficial effects were initially ascribed to the transdif ferentiation of MSCs into lung parenchymal cells such as type II pneumocytes (11, 25) . However, this event rarely occurs in vivo (11) . The low rate of in vivo engraftment and differentiation into lung tissue suggests that the therapeutic effects of stem cell trans plantation might not be primarily mediated by regeneration. An equal or better therapeutic efficacy in preventing or revers ing established BPD was observed with MSCconditioned me dia compared with MSC (13, 26, 27) . More recently, Lee et al. (28) have reported that microvesicles released by MSC exosomes are the major paracrine antiinflammatory and therapeutic mediators of MSCs in hypoxiainduced pulmonary hyperten sion. Collectively, these findings suggest that the protective ef fects of stem cell transplantation might be predominantly me diated by paracrine, rather than regenerative, mechanisms. The use of MSC secretomes rather than stem cells could be an excit ing, promising new therapeutic approach for BPD, especially since it circumvents the theoretical concerns associated with live cell treatments, such as tumor formation.
The specific humoral substances secreted by the transplant ed MSCs that are responsible for the protective paracrine activ ity have not yet been elucidated. In our previous experiments, we observed that significantly reduced levels of growth factors such as vascular endothelial growth factor (VEGF) and hepato cyte growth factor (HGF) were significantly improved with MSCs transplantation (17) . Moreover, the knockdown of VEGF secre tion by the MSCs using transfection with small interfering RNA specific for human VEGF abolished the protective effects of MSCs in hyperoxic lung injury (18) . These protective effects in cluded the attenuation of impaired alveolarization and angio genesis, reduction in apoptotic cells and alveolar macrophages, and downregulation of proinflammatory cytokine levels (18) . Overall, these findings suggest that growth factors such as VEGF, which are secreted by the transplanted MSCs, are critical para crine factors that mediate the protective effects of MSCs against hyperoxic lung injuries.
Determining the optimal route, dose, and timing of MSC transplantation Determining the optimal route of MSC transplantation is a crit ical issue that needs to be resolved for future successful clinical translation of stem cell therapies for protection against BPD. In jured lungs produce chemotactic factors that cause MSCs to proliferate and migrate toward the injury (28) . Furthermore, systemically administered MSCs have been shown to home and localize to an injured lung (29) . Local intratracheal trans plantation of MSCs at four times lesser doses produced more effective engraftment of donor cells and attenuation of hyper oxiainduced lung injury than with systemic intravenous or in traperitoneal administration (11) . These findings suggest that the local intratracheal rather than systemic intravenous or in traperitoneal transplantation of MSCs might be an optimal route of delivery for treating premature infants with BPD.
Determination of the optimal dose of MSCs for transplanta tion is another important issue that needs to be addressed for successful clinical translation. In our previous study (15) 4 cells were necessary for effective antiinflammatory, an tifibrotic, and antioxidative activity. In the light of these find ings, further studies to determine the optimal dose of human UCB derived MSCs for potential clinical benefit in human pre term neonates are planned.
While the therapeutic efficacy of MSC transplantation in BPD has already been shown (11) , the optimal timing of administra tion is another critical issue that remains to be established. There fore, we attempted to determine the optimal timing by compar ing the therapeutic efficacy of early (at P3) versus late (at P10) intratracheal transplantation of MSCs (17) . We observed that hyperoxiainduced lung injuries such as impaired alveolariza tion, increased apoptosis, oxidative stress, inflammation, and fibrosis, as well as reduced VEGF and HGF levels were signifi cantly attenuated with early but not late transplantation. These findings suggest that the therapeutic time window of MSC trans plantation for BPD may be narrow during the early but not the late phase of inflammatory responses.
Long-term safety and outcome of MSC transplantation
Peirro et al. (20) reported that both human umbilical cordde rived perivascular cells and MSCs exerted short and longterm (6 months) therapeutic benefits including persistent improve ment in lung structure and exercise capacity, despite the low engraftment of cells. Moreover, no tumor formation was ob served, and the beneficial effects of intratracheal transplanta tion of MSCs in neonatal hyperoxic lung injuries were evident at P5. These beneficial effects, which included improved alveo lar and vascular growth, were sustained for a prolonged recov ery period without any longterm adverse effects up to P70 (16) . Overall, these findings support the assumption that transplan tation of MSCs to prevent or treat BPD in premature infants at a critical early time point might modify and improve the long term respiratory morbidities of BPD.
PHASE I CLINICAL TRIAL OF MSC FOR BPD
The safety and feasibility of transplanting allogeneic human UCBderived MSCs in preterm infants was assessed. Intratra cheal transplantation of MSCs was performed in 9 preterm in fants (3 received 1 × 10 7 cells/kg and 6 received 2 × 10 7 cells/kg) who had a very high risk for developing BPD. The infants in this phase I clinical study had a mean gestational age of 25.3 ± 0.9 weeks, a mean birth weight of 793 ± 127 g and a mean birth age of 10.4 ± 2.6 days (30). The transplantation was well tolerated, without any serious adverse events or doselimiting toxicity. Tracheal aspirate cytokine levels at day 7 were significantly re duced compared with the baseline levels. Moreover, BPD se verity which classified as mild, moderate, and severe according to the consensus of NICHD workshop (31) , was significantly lower in the transplant recipients compared with the gestation al age, body weight, and respiratory severitymatched control group. Overall, these findings suggest that intratracheal trans plantation of allogeneic human UCBderived MSCs in very pre term infants at the highest risk for developing BPD is safe and feasible. A longterm followup safety study (NCT01632475) on MSCtreated preterm infants and a phase II doubleblind ran domized controlled trial to assess the therapeutic efficacy (NCT 01828957) are currently underway.
CONCLUSIONS
In recent years, we have broadened our knowledge and under standing of stem cell therapy for neonatal lung injury. Contri butions to this advancement include the various translational research studies supporting the therapeutic potential, safety profile, optimal route, optimal timing, optimal dose, and poten tial efficacy marker of stem cell therapies for BPD. Moreover, the first phase I clinical trial of MSC transplantation for BPD was conducted successfully, proving its safety and feasibility in the preterm infants. This progress has moved human stem cell therapy for BPD one step closer to clinical translation (Tables 1,  2) . We are currently conducting two essential studies to be in troduced clinically. The first is a phase II clinical trial to assess the therapeutic efficacy (NCT01828957), and the second is a longterm followup safety assessment study of the MSC trans 
